drugset / Trial / NCT07752407

A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks

NCT07752407 ↗

Phase 3 Recruiting 500 enrolled Phathom Pharmaceuticals, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The main objective is to assess the efficacy of vonoprazan (10 mg as needed) compared to placebo (as needed) in relief of episodic heartburn at 2 hours that is sustained for 24 hours over 12 weeks of treatment in participants with non-erosive gastroesophageal reflux disease (GERD).

Timeline

Start
2026-09-25
Primary completion
2027-10-20
Completion
2028-01-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Vonoprazan Other / unclassified 10 mg Oral